Acoustic neuroma

The acoustic neuroma is also known as vestibular schwannoma and is a benign primary intracranial tumour. More than 95 % of all acoustic neuromas only occur on one sight. In connection with neurofibromatosis type II they typically appear on both sides.
   

Please note that the following threads of our forum are currently only available in German language.

Aktuelles aus dem Akustikusneurinom Forum

Histology of Acoustic Neuroma

  • slowly growing, benign tumours (WHO I)
  • arise from Schwann cells

 

Epidemiology of Acoustic Neuroma
 

  • occur in in middle age
  • frequency: 1/100 000
  • less than 5 % of acoustic neuroma are on both sides

 

Symptoms of Acoustic Neuroma
 

  • hearing loss (mostly on one side)
  • noise in the ear
  • dizziness
  • equilibrium disturbance
  • disturbance of sensitivity in the face
  • paralysis of the facial nerve (facial paralysis)
  • uncertain gait

 

Diagnosing Acoustic Neuroma
 

  • ENT-diagnostic: hearing and balance tests, electrophysiological examination
  • MRI and CT
  • Contrast enhancing and clear demarcation of the tumour
  • in MRI: hypo-isointense in T1, hyperintense in T2
  • in CT: bony extension of the inner ear canal
  • main localisation in cerebellopontine angle or inner ear canal

 

Therapy of Acoustic Neuroma
 

  • „wait and scan“
  • if possible, complete surgical removal
  • alternatively radiosurgery and stereotectic radiotherapy

 

Therapy of Recurrent Acoustic Neuroma
 

  • re-operation
  • irradiation, possibly radiosurgery

 

Aftercare of Acoustic Neuroma
 

  • after therapy: MRI´s up to five years

 

Course of Acoustic Neuroma
 

  • very slowly growing, approximately 1 to 5 mm per year
  • also stangnant cases are known

 

Prognosis of Acoustic Neuroma
 

  • after complete surgical removal normal life expectancy can be reached
  • only in very rare cases malignant forms have been seen

Latest News

NOA-Jahrestagung II

Update zu laufenden und geplanten NOA-Studien und Zukunftsvisionen

 > more

NOA-Jahrestagung I

Neues von der WHO-Klassifikation der Hirntumoren

 > more

Individualisierte Therapie

NOA-20-Studie untersucht Therapiewahl auf Basis molekularer Marker

 > more